This study is to establish the nomogram model and provide clinical therapy decision-making for extensive-stage small-cell lung cancer (ES-SCLC) patients with different metastatic sites using the Surveillance, Epidemiology, and End Results (SEER) Program.A total of 10,025 patients of ES-SCLC with metastasis from January 2010 to December 2016 were enrolled from the SEER database. All samples were randomly divided into a derivation cohort and a validation cohort, and the derivation cohort was divided into 6 groups by different metastatic sites: bone, liver, lung, brain, multiple organs, and other organs. Using Cox proportional hazards models to analyze candidate prognostic factors, screening out the independent prognostic factors to establish the nomogram. Compare the different models by Net reclassification improvement and integrated discrimination improvement. Concordance index (C-index) and the calibration curve were used to verify the prediction efficiency of the nomogram in the derivation cohort and validation cohort.In the derivation cohort, the median overall survival was 7 months. The overall survival rates at 6-month, 1-year, and 2-year were 55.07%, 24.61%, and 7.56%, respectively. The median survival time was 10, 8, 7, 9, 7, and 6 months for the 6 groups of different metastatic sites: other, bone, liver, lung, brain, and multiple organs, respectively. Age, sex, race, T, N, distant metastatic site, and chemotherapy were contained in the final nomogram prognostic model. The C-index was 0.6569777 in the derivation cohort and 0.8386301 in the validation cohort.The survival time of ES-SCLC patients with different metastatic sites was significantly different. The nomogram can effectively predict the prognosis of individuals and provide a basis for clinical decision-making.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437828PMC
http://dx.doi.org/10.1097/MD.0000000000021798DOI Listing

Publication Analysis

Top Keywords

derivation cohort
20
metastatic sites
16
prognostic factors
12
extensive-stage small-cell
8
small-cell lung
8
lung cancer
8
nomogram model
8
establish nomogram
8
es-sclc patients
8
patients metastatic
8

Similar Publications

Introduction: Immune checkpoint inhibitors (ICI) have improved outcomes in non-small cell lung cancer (NSCLC). Nevertheless, the clinical benefit of ICI as monotherapy or in combination with chemotherapy remains widely varied and existing biomarkers have limited predictive value. We present an analysis of ENLIGHT-DP, a novel transcriptome-based biomarker directly from histopathology slides, in patients with lung adenocarcinoma (LUAD) treated with ICI and platinum-based chemotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Hepatitis B virus (HBV) is a major global health concern linked to liver disease and cancer, with research focusing on genetic factors that affect its evolution.
  • Recent studies highlighted the ECM1 gene, specifically two polymorphisms (rs3834087 and rs3754217), which may influence HBV pathogenesis, particularly in an African cohort analyzed in this research.
  • The study found that the heterozygous genotype of rs3754217 appears to protect against chronic hepatitis, suggesting that certain genetic variations may impact the severity of the disease in infected individuals.
View Article and Find Full Text PDF

Intersection of rare pathogenic variants from TCGA in the All of Us Research Program v6.

HGG Adv

January 2025

Department of Biology, Brigham Young University, Provo, UT, 84061, USA; Simmons Center for Cancer Research, Brigham Young University, Provo, UT 84602, USA. Electronic address:

Using rare cancer predisposition alleles derived from The Cancer Genome Atlas (TCGA) and high cancer prevalence (14% of participants) in All of Us (version 6), we assessed the impact of these rare alleles on cancer occurrence in six broad groups of genetic similarity provided by All of Us: African/African American (AFR), Admixed American/Latino (AMR), East Asian (EAS), European (EUR), Middle Eastern (MID), or South Asian (SAS). We observed that germline susceptibility to cancer consistently replicates in EUR-like participants but less so in other participants. We found that All of Us participants from the EUR (p = 1.

View Article and Find Full Text PDF
Article Synopsis
  • Cervical cancer is the fourth most common cancer in women globally, and this study introduces a deep learning framework to predict molecular subtypes in HPV-positive cervical squamous cell carcinoma using histology slides.
  • The research analyzed three cohorts with 545 patients, demonstrating that the Digital-CMS scores can effectively predict both disease-specific and disease-free survival outcomes.
  • Furthermore, the study found significant differences in the tumor microenvironment between subtypes, highlighting potential biomarkers and therapeutic targets that could guide clinical applications for better patient management.
View Article and Find Full Text PDF

Can parenchymal volume analysis replace nuclear renal scans for split renal function before and after partial nephrectomy with warm ischemia?

Urol Oncol

January 2025

Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China; State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, P. R. China. Electronic address:

Article Synopsis
  • The study evaluates parenchymal volume analysis (PVA) as a potential alternative to nuclear renal scan (NRS) for assessing split renal function (SRF) before and after partial nephrectomy (PN) with warm ischemia.
  • Preoperatively, PVA showed a strong correlation with NRS findings, indicating its reliability for SRF assessment (49.4% vs. 50.0%, P = .501).
  • Results suggest that while PVA is consistent with NRS preoperatively, the efficacy of PVA remains uncertain for post-operative SRF evaluation after PN, indicating a need for further investigation.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!